MEDI-575

DRUG4 trials

Sponsors

MedImmune LLC, AstraZeneca

Conditions

Advanced Solid MalignanciesCancerGlioblastoma MultiformeNon-small Cell Lung Cancer

Phase 1

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

CompletedNCT00816400

MedImmune LLCCancer

Start: 2009-03-02End: 2012-01-19Updated: 2018-06-26

A Study of MEDI-575 in Patients With Advanced Solid Malignancies

CompletedNCT01102400

AstraZenecaAdvanced Solid Malignancies

Start: 2010-03-31End: 2012-11-30Updated: 2013-02-06

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer

TerminatedNCT01268059

MedImmune LLCNon-small Cell Lung Cancer

Start: 2010-12-16End: 2013-09-11Updated: 2020-12-23

Phase 2

A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

CompletedNCT01268566

MedImmune LLCGlioblastoma Multiforme

Start: 2011-01-31End: 2012-11-30Updated: 2017-04-06

Related Papers

A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors.

2015-07-304 citations